Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus XELOX for Gastric Signet Ring Carcinoma
NCT03355612Phase 3Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of Rivoceranib in Gastric signet ring cell carcinoma (SRCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
Gastric signet ring cell carcinoma (SRCC)
Beyond the preview
Go deeper on NCT03355612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355612.